Related Experiment Video
Updated: May 5, 2026

Chronic Salmonella Infection Induced Intestinal Fibrosis
Published on: September 22, 2019
Case Report: Severe kidney involvement in a case of very early onset inflammatory bowel disease
Enrico Drago1,2, Roberta Carfora1, Barbara Cafferata3
1Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINOGMI), University of Genoa, Genova, Italy.
Background:
Patients affected by very early onset inflammatory bowel disease (VEO-IBD) are frequently refractory to standard treatments. Despite the lack of randomized clinical trials, vedolizumab emerged as an effective and safe alternative treatment in VEO-IBD resistant to TNF antagonists. Here, we present a case of VEO-IBD with ulcerative colitis (UC) phenotype developing renal injury after vedolizumab administration.
Case Presentation:
An 11-year-old female patient with VEO-UC was referred to our clinic for fever, nausea, and fatigue. She was treated with vedolizumab for 1 year due to steroid-dependent disease and failure of multiple therapies, including anti-TNF agents. At admission, she was in steroid-free clinical and endoscopic remission, with leukocytosis, increased inflammatory markers, and a rise in serum creatinine. Urine samples revealed persistent leukocyturia over the past 8-10 months with the absence of lower urinary tract symptoms and negative serial urine culture. MRI showed swollen-looking kidneys with bilateral irregular Diffusion-Weighted Imaging (DWI) signal restriction. Kidney biopsy revealed the presence of acute tubular damage with a mixed interstitial inflammatory infiltrate consistent with drug-induced acute tubulointerstitial nephritis (TIN). After prompt start of systemic glucocorticoid therapy and temporary discontinuation of vedolizumab, normalization of renal function and urinalysis was observed. Vedolizumab was restarted after 2 months, pre-medicated with steroids. The follow-up renal biopsy performed after 6 months showed a regression of the histological pattern, with chronic signs characterized by mild tubular atrophy and interstitial fibrosis.
Conclusion:
Vedolizumab-related acute TIN is a potentially severe complication, rarely described in adult patients. We report the first case of VEO-IBD with a probable vedolizumab-related acute TIN treated with corticosteroids, with a good response and maintenance of vedolizumab. Persisting sterile leukocyturia could represent an early sign.
Related Concept Videos
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory Bowel Disease I: Introduction
Inflammatory Bowel Disease II: Ulcerative Colitis
Inflammatory Bowel Disease III: Crohn's Disease
Inflammatory Bowel Disease IV: Clinical Manifestations

